Pleconaril - Apodemus

Drug Profile

Pleconaril - Apodemus

Alternative Names: APO-P001

Latest Information Update: 16 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apodemus
  • Class Antivirals; Oxadiazoles; Small molecules
  • Mechanism of Action RNA inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 28 Mar 2018 Phase-II clinical trials in Alzheimer's disease (Adjunctive treatment) in Czech Republic (PO) (EudraCT2017-004125-32)
  • 13 Sep 2017 Oslo University Hospital plans a phase II trial for Type-1 diabetes in Sweden (EudraCT2015-003350-41)
  • 04 Sep 2016 Apodemus terminates a phase II clinical trial in Amyotrophic lateral sclerosis (Combination therapy) in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top